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Introduction
Cryptococcosis is an opportunistic fungal disease
caused by Cryptococcus neoformans, an encapsulated dimorphic fungus. It has two subspecies: Cryptococcus
neoformans var. neoformans and Cryptococcus neoformans
var. gattii. Each subspecies cause disease in humans.
C. neoformans var. neoformans has been connected to infection in immunosuppressed patients worldwide; C.
neoformans var. gattii has been described in relation to
infections in immunocompetent patients but its distribution is limited to tropical and subtropical countries.
Infection occurs by inhaling the microorganism present
in bird excrement, most commonly from pigeons. This
produces an initial infection in the lungs, from where
it can spread by hematogenous dissemination to other
organs—mainly meninges and the central nervous
system—causing meningitis and encephalitis.[1, 2] It
also may remain latent and reactivate when immunity
mechanisms fail. The most common manifestation of
this fungus, both in immunosuppressed and immunocompetent patients, is neurological.
Isolated pulmonary cryptococcosis occurs in approximately 10-30% of cases, and is more frequent in immunosuppressed patients.[3, 4] Existing literature is focused on the HIV population, and descriptions of this
disease in non-HIV patients are scarce.[5]
We present a patient with lymphoma on chemotherapy,
with pulmonary and pleural involvement with C. neoformans in the pleural fluid, with an unfavorable clinical
course.

Clinical case
We present a 65-year-old patient, former smoker, with
hypertension, gallstones, and stage III mantle cell lymphoma admitted with respiratory symptoms. He had
undergone his first cycle of scheduled chemotherapy
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a week previously. He was admitted with worsening
cough, expectoration, fever and concern for bacteremia.
Upon physical examination, he was febrile and tachypneic. He had good bilateral air entry, bilateral isolated
rhonchi, right-sided basilar crackles, and painless bilateral lateral cervical, supraclavicular, axillary and inguinal lymphadenopathy. His complete blood count
(CBC) showed his hematocrit was 22%, hemoglobin
7.8 g/dL, white blood cells 9,700/mm3 and platelets
522,000/mm3 . Tests for HIV, Hepatitis B and Hepatitis C were negative. A chest computerized tomography
(CT) scan was abnormal (Figure 1).
The patient was initially felt to have hospital-acquired
pneumonia. Blood cultures and sputum tests were
ordered. An empiric treatment with piperacillintazobactam was started with a satisfactory clinical response. All cultures were initially negative. A week
after admission, fever and hypoxemia recurred. A CT
chest scan was repeated (Figure 2).
A thoracentesis was performed, with results as follows:
slightly bloody pleural fluid, 175/mm3 red blood cells,
740/mm3 white blood cells (lymphocyte predominant),
glucose 100 mg/dL, protein 2.1 g/dL, and LDH 233
U/L. These results were consistent with uncomplicated
effusion.
Pleural fluid culture tested negative for common organism pathogens and positive for Cryptococcus neoformans.
Cryptococcal antigen in the blood and fungal blood
cultures remained negative. Treatment with Amphotericin B was initiated. The patient’s condition continued to worsen, with acute respiratory distress requiring orotracheal intubation and respiratory mechanical
ventilation until he died due to multi-organ failure.

Discussion
Pulmonary cryptococcosis may develop in immunocompetent or immunocompromised patients, such as
1
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Figure 1. Alveolar infiltrates with right upper, middle, and lower lobe involvement, with consolidation areas, ground-glass areas, and diffuse
micronodules.

those with HIV or other underlying medical conditions, including lymphoma, leukemia, solid organs or
bone marrow transplant recipients, systemic lupus erythematosus, sarcoidosis, diabetes mellitus, rheumatoid
arthritis, and chronic treatment with corticosteroids,
immunomodulators, or anti-TNF-α agents.
The clinical picture of cryptococcosis differs depending on the patient’s immune status. In immunocompetent patients, the infection is self-limited and minimally symptomatic; in the immunocompromised host,
the disease can be severe and disseminated.
Clinical manifestations of pulmonary cryptococcosis
varies from mild symptoms such as cough, expectoration, prolonged febrile syndrome, weight loss, and
anorexia to disseminated cryptococcosis involving several organs. This is why it is necessary to test for CNS
involvement in immunosuppressed patients.[6, 7]
There are three types of radiological patterns in pulmonary cryptococcosis: (1) nodular mass, (2) consolidation and (3) reticulo-alveolar opacities. Nodules are
the most frequent radiological finding in immunocompetent and immunosuppressed patients. These can be
multiple, single, or cavitated with regular or irregular contours and may have confluent or be diffused in
distribution.[8, 9] Consolidations, reticular infiltrates,
ground-glass opacities, a halo sign and mediastinal,
or hilar adenopathy may also be found. Other less
frequent findings are pleural effusion, cavitation and
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endobronchial lesions. After treatment of pulmonary
cryptococcosis, bronchiectasis and fibrotic areas may
appear.[10, 11]
The yield from a pleural fluid culture for Cryptococcus
is approximately 50%. Another method for diagnosis
is the detection of Cryptococcal antigen in the pleural
fluid. The title of antigenemia seems to be related to
the route of dissemination—contiguous dissemination
via subpleural pulmonary lesions is usually more common than bloodborne dissemination.[12]
In a review of patients with HIV and pulmonary cryptococcosis, 10% had pleural involvement and most
cases were accompanied by disseminated cryptococcosis. There are only 50 reported cases of pleural cryptococcosis described in the literature.[3, 12]
In a Young et al review, 14 of the 30 patients with pleural effusion due to Cryptococcus have a disease localized to the thorax and 16 have disseminated disease.
Predisposing disease or immunosuppressive treatment
were found in 17 patients. Cultures of pleural fluid
for cryptococci were positive in 11 of 26 patients. (in
the other 15 patients, the diagnosis was established by
histopathological study of lung samples).[13]
The guidelines from the Infectious Diseases Society
of America (IDSA) for cryptococcal disease recommend treatment of disseminated disease with CNS involvement or severe pulmonary involvement with two

2

ULJRI

Pleural Effusion as a Manifestation of Pulmonary Cryptococcosis

Figure 2. Bilateral pleural effusion with a right predominance and associated bibasilar consolidated areas and pleuro-pulmonary fibrous tracts.

weeks of Liposomal Amphotericin and Flucytosine,
continuing liposomal amphotericin B and flucytosine,
then continuation with oral Fluconazole for maintenance and suppression. When available, therapy doubled with amphotericin Band fluconazole may also be
considered as an alternative when there is lack of access
to flucytosine.[15]

Conclusion
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Pulmonary cryptococcosis is difficult to diagnose in
non-AIDS immunosuppressed patients as the clinical
and radiological manifestations are atypical. Pleural involvement is uncommon. Clinical suspicion and invasive methods are necessary to establish the diagnosis
and appropriate treatment.
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